• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

20.24 -0.12 (-0.59%)
Official Closing Price Updated: 7:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,099,212
Open 20.28
Bid (Size) 20.00 (100)
Ask (Size) 20.41 (200)
Prev. Close 20.36
Today's Range 20.17 - 20.39
52wk Range 12.99 - 20.39
Shares Outstanding 1,557,765,596
Dividend Yield 3.35%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
October 23, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
October 19, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire

Performance

52-Week Range 0.7% below 52-week high
20.24
12.9952W Low 20.3952W High
1 Week 0.7% below 1-week high
19.551W Low 20.391W High

Takeda Pharmaceutical Company Limited American Depositary Shares (each (TAK) traded between $12.99 and $20.39 over the past 52 weeks and last traded at $20.24, 0.7% below its 52-week high. Over the past week it ranged between $19.55 and $20.39.

Past 12 Months
+3.2%
+7.6%
+17.4%
+21.7%
+29.6%
+44.0%
1W +$0.63
1M +$1.43
3M +$3.00
6M +$3.61
YTD +$4.62
1Y +$6.18

TAK was +44.0% over the past year, +21.7% over six months, +29.6% year to date, +3.2% in the last week.

12 Months vs Market
TAK
+44.0%
DIA
+11.6%
SPY
+13.1%
QQQ
+15.4%
IWM
+11.9%

Over the past 12 months TAK returned +44.0% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.74× 3-mo avg
Today 2,099,212 3-mo avg 2.8M
1W
2.6M
1M
2.8M
3M
2.8M
6M
3.0M
YTD
3.0M
1Y
3.0M

TAK most recently traded 2,099,212 shares against a 3-month average daily volume of 2.8M.

More News

Read More
News headline image
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
October 14, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
October 14, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
September 30, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
September 22, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
September 18, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
September 14, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
September 09, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
August 31, 2026
Via The Motley Fool
News headline image
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
August 28, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 24, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda (TAK) Q1 2026 Earnings Call Transcript ↗
August 07, 2026
Via The Motley Fool
Topics Earnings
News headline image
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 05, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Pharmaceutical Q1 Earnings Call Highlights ↗
July 30, 2026
Via MarketBeat
Topics Earnings
News headline image
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
July 30, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
July 16, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
July 12, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
June 24, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
June 15, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
June 11, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
June 09, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
May 18, 2026
From Hagens Berman
Via Business Wire
News headline image
Takeda Pharmaceutical Q4 Earnings Call Highlights ↗
May 15, 2026
Via MarketBeat
Topics Earnings
News headline image
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
May 13, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire

Frequently Asked Questions

Is Takeda Pharmaceutical Company Limited American Depositary Shares (each publicly traded?
Yes, Takeda Pharmaceutical Company Limited American Depositary Shares (each is publicly traded.
What exchange does Takeda Pharmaceutical Company Limited American Depositary Shares (each trade on?
Takeda Pharmaceutical Company Limited American Depositary Shares (each trades on the New York Stock Exchange
What is the ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each is TAK on the New York Stock Exchange
What is the current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 20.24
When was Takeda Pharmaceutical Company Limited American Depositary Shares (each last traded?
The last trade of Takeda Pharmaceutical Company Limited American Depositary Shares (each was at 10/23/26 07:00 PM ET
What is the market capitalization of Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The market capitalization of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 31.53B
How many shares of Takeda Pharmaceutical Company Limited American Depositary Shares (each are outstanding?
Takeda Pharmaceutical Company Limited American Depositary Shares (each has 32B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap